Advanced Accelerator Applications
Accelerator Applications (AAA) is a radiopharmaceutical company founded in 2002 that develops innovative diagnostic and therapeutic
products. AAA’s main focus is in the field of molecular imaging and targeted, individualized therapy for patients with serious
conditions (“Personalized Medicine”). AAA currently has 17 production and R&D facilities able to manufacture both
diagnostics and therapeutic MNM products, and has over 400 employees in 11 countries (France, Italy, UK, Germany, Switzerland,
Spain, Poland, Portugal, Israel, U.S. and Canada). In 2014, AAA reported sales of €69.9 million (+29.9% vs. 2013). AAA is
listed on the Nasdaq Global Select Market under the ticker “AAAP”. For more information please visit: www.adacap.com
Molecular Nuclear Medicine (“MNM”)
Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images
of organs and lesions and to treat various diseases, such as cancer. The technique works by injecting targeted radiopharmaceuticals
into the patient’s body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear
Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single
Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer,
cardiovascular diseases, neurological disorders and other diseases in their early stages.
About Johns Hopkins Technology
Johns Hopkins Technology Ventures (JHTV) serves Johns Hopkins researchers and inventors as
a licensing, patent and technology commercialization office and acts as an active liaison to parties interested in leveraging
university research or materials for academic or corporate endeavors. JHTV helps develop new discoveries and inventions into products
and services that benefit society and transform the world. In 2014, JHTV secured more than $16 million in licensing revenue, possessed
more than 2,000 active issued patents and created 13 new startup companies. For more information about Johns Hopkins Technology
Ventures, opportunities to collaborate, start a technology venture or license a technology, visit http://ventures.jhu.edu/
Statement Regarding Forward-Looking Statements
release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press
release, including statements regarding the Company's strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future
events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments
to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies,
the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals